Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 1315 new people
  • 107 new organizations
  • 1149 new photos
  • 1999 job history records for people in our database
  • 713 education records for people in our database
  • 3184 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 1 new person through the revolving door
  • 132 new policy reports
  • 15 new trips to our privately funded travel database
  • 356 new personal financial disclosures
  • 9208 new press releases
  • 5 new town halls
  • 37 new hearings

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

Information Management: FDA's FOIA Fees

  Premium   Download PDF Now (3 pages)
Report Type Reports and Testimonies
Report Date June 10, 1993
Report No. GGD-93-47R
Subject
Summary:

Pursuant to a congressional request, GAO provided information on the Food and Drug Administration's (FDA) retention of fees for Freedom of Information Act (FOIA) information request processing, focusing on whether FDA has shortened its processing time for FOIA requests since 1990. GAO found that: (1) although the overall time FDA needed to process FOIA requests has increased by about 19 percent since 1988, request processing times have only increased by 9 percent since 1990; (2) the number of FOIA requests and FDA staff years assigned to FOIA work increased between 1990 and 1992; (3) FDA believed it could not sufficiently determine the impact of fee retention on FOIA request processing because other factors, including request complexity, staff inexperience and turnover, and policy and procedural changes, affected the average request processing time; (4) retention fees accounted for only 10 percent of actual FOIA request processing costs; and (5) although FDA lacked adequate data to compare its response times with other agencies, it believed that its response times were reasonable.

« Return to search Government Accountability Office reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com